Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Non-Small Cell Lung Cancer

In brief

This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor Tuvusertib in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer (nsqNSCLC) that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies..

Key facts

Study ID

NCT05882734

Run by

EMD Serono Research & Development Institute, Inc.

People needed

61

Starts

2023-09-13

Expected to finish

2026-09-30

Last updated by the study team

2026-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who are diagnosed with nsqNSCLC histologically or cytologically confirmed
• Participants with Radiologically confirmed/documented disease progression during or after the following systemic therapies (all required):
• At most, 1 line of anti-PD-(L)1 therapy for locally advanced or metastatic disease. Rechallenge with the same anti-PD-(L)1 for disease considered sensitive to anti-PD-(L)1 therapy (e.g. after a treatment break) is considered 1 line
• Platinum-based therapy for locally advanced or metastatic disease, given in combination or sequentially with anti-PD-(L)1 therapy. Participants who received adjuvant platinum-based therapy meet this criterion if disease progression occurred within 6 months from the last dose that the participant received that therapy. No additional cytotoxic therapies after progression on platinum-based therapy are allowed
• Prior best overall response of stable disease or better with anti-PD-(L)1 therapy
• Disease progression must have occurred while the participant has been receiving anti-PD-(L)1 therapy or within 16 weeks of the last dose of anti-PD-(L)1 therapy
• Participants with Measurable disease per RECIST v1.1
• Participants with Eastern Cooperative Oncology Group (ECOG) PS 0 or 1
• Adequate hematological, hepatic, and renal function as defined in the protocol.
• Phase 2a part only: central liquid biopsy analysis of tumor molecular alterations with an assay with appropriate regulatory status
• Other protocol defined inclusion criteria could apply

You may not qualify if…

• Participants with tumors harboring actionable epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic aberrations. Participants with tumors with other actionable aberrations are eligible and allowed to have received up to 1 line of available targeted therapy
• Participants with history of additional malignancy within 3 years before the date of enrollment. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator, with concurrence of the Sponsor's Medical Monitor, is considered cured with minimal risk of recurrence within 3 years
• Participants with known brain metastases, unless clinically stable
• Participant with history of (noninfectious) pneumonitis that required systemic corticosteroids or current pneumonitis/interstitial lung disease
• Other protocol defined exclusion criteria could apply

Where it is running

• Asan Medical Center — Seoul, South Korea
• Samsung Medical Center — Seoul, South Korea
• UCLA Hematology and Oncology - Santa Monica — Santa Monica, California, United States
• UPMC Cancer Center — Pittsburgh, Pennsylvania, United States
• Tennessee Cancer Specialists - Biomedical Research — Knoxville, Tennessee, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Millennium Research & Clinical Development — Houston, Texas, United States
• Virginia Cancer Specialists, PC — Fairfax, Virginia, United States
• Institut Jules Bordet - Department of Institut Jules Bordet' — Anderlecht, Belgium
• UZA - Oncology — Edegem, Belgium
• Jessa Ziekenhuis Hospital — Hasselt, Belgium
• Universitair Ziekenhuis Brussel - UZB — Jette, Belgium
• UZ Leuven — Leuven, Belgium
• CHU de Liège - PARENT — Liège, Belgium
• CHU Angers - Hôpital Larrey - Service de Pneumologie — Angers, France
• Centre Hospitalier Intercommunal de Créteil - Service de Pneumologie — Créteil, France
• CHU Limoges - Hôpital Dupuytren - Unite d'Oncologie Thoracique et Cutanée — Limoges, France
• Hôpital de la Timone - CPCEM CIC - Bat F 1er étage — Marseille, France
• Hopital Arnaud de Villeneuve - Service de Pneumologie-Addictologie — Montpellier, France
• Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Unité d'Explorations Fonctionnelles Respiratoires — Pessac, France
• ICO - Site René Gauducheau - Service d'Oncologie medicale — Saint-Herblain, France
• Universitaetsklinikum Giessen und Marburg GmbH - Medizinische Klinik und Poliklinik III — Giessen, Germany
• Universitaetsklinikum Leipzig AoeR - Med. Klinik u. Poliklinik I - Abt. Pneumologie — Leipzig, Germany
• Sana Klinikum Offenbach GmbH - Medizinische Klinik IV — Offenbach, Germany
• Kanagawa Cancer Center — Yokohama, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.